SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

8 Oct 2015 07:00

RNS Number : 5861B
Victrex PLC
08 October 2015
 



 

 

 

 

 

 

8 October 2015

 

Victrex plc - Full year pre-close trading update

 

"A good finish to 2015"

 

Victrex plc, an innovative world leader in high performance polymer solutions, today announces its full year pre-close trading update for the financial year ended 30 September 2015, ahead of its preliminary results on 8 December 2015.

 

Victrex delivered a good finish to 2015, with overall performance in line with our expectations, including a robust fourth quarter (Q4). For the year as a whole, the value of our balanced portfolio helped to drive growth and fully overcome headwinds including weaker sales in Oil & Gas, the effects of US Spine market consolidation on our Invibio medical business and the significant impact from foreign currency this year.

 

On a reported basis, full year Group revenue of £263.5m was 4% ahead of the prior year (FY 2014: £252.6m), with Q4 Group revenue of £68.7m being flat on the prior year period. Foreign currency, at a profit level, was a headwind of approximately £8m for the full year, which we will fully overcome.

 

At a volume level, full year Group sales volume of 4,217 tonnes was 19% ahead of the prior year (FY 2014: 3,551 tonnes). Q4 Group sales volume of 1,119 tonnes was 6% ahead of the prior year period (Q4 2014: 1,056 tonnes). Sales volumes reflect our overall momentum in VPS remaining positive during the fourth quarter, with growth across Aerospace, Automotive, General Industrial and strong Consumer Electronics volumes offsetting Oil & Gas, as previously communicated.

 

Invibio performance was in line with our previous guidance, with full year revenue of £50.5m being 5% down compared to the prior year (FY 2014: £53.4m). This reflects the effects of consolidation in the US Spine market.

 

Outlook

Our overall growth momentum remains positive as we start our new financial year. Whilst we are mindful of the continuing weakness in Oil & Gas and the need to improve Invibio performance in 2016, our balanced portfolio keeps us well placed to continue driving growth and creating value, in line with our long term strategy.

 

Enquiries:

 

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

David Hummel, Chief Executive +44 (0) 1253 897700

 

Pendomer Communications:

Charles Armitstead +44 (0) 203 603 5220

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions focused on the Aerospace, Automotive, Electronics, Energy and Medical markets. Every day, millions of people rely on products or applications which contain our polymers, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are delivering leading edge solutions to shape future performance for our customers and our markets, and to drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGQWUUPAGAM
Date   Source Headline
30th Nov 20189:39 amRNSTotal Voting Rights
28th Nov 20189:59 amRNSDirector Declaration
19th Nov 201812:14 pmRNSDirector/PDMR Shareholding
14th Nov 201810:01 amRNSDirector Declaration
31st Oct 201810:29 amRNSTotal Voting Rights
17th Oct 201811:23 amRNSDirector/PDMR Shareholding
28th Sep 20189:17 amRNSTotal Voting Rights
18th Sep 201812:06 pmRNSDirector/PDMR Shareholding
31st Aug 201810:52 amRNSTotal Voting Rights
22nd Aug 201812:46 pmRNSHolding(s) in Company
17th Aug 201811:31 amRNSDirector/PDMR Shareholding
31st Jul 201810:56 amRNSTotal Voting Rights
27th Jul 20184:01 pmRNSHolding(s) in Company
25th Jul 201811:16 amRNSDirector/PDMR Shareholding
25th Jul 20187:00 amRNSInterim Management Statement
17th Jul 201812:47 pmRNSDirector/PDMR Shareholding
29th Jun 20189:26 amRNSTotal Voting Rights
19th Jun 20183:25 pmRNSDirector/PDMR Shareholding
1st Jun 20189:04 amRNSBlock listing Interim Review
31st May 20181:29 pmRNSTotal Voting Rights
17th May 20182:37 pmRNSDirector/PDMR Shareholding
16th May 20183:47 pmRNSDirector/PDMR Shareholding
14th May 20187:01 amRNSDirectorate Change
14th May 20187:00 amRNSHalf-year Report
1st May 201811:42 amRNSTotal Voting Rights
30th Apr 201811:40 amRNSAdditional Listing
17th Apr 20184:28 pmRNSDirector/PDMR Shareholding
28th Mar 201810:00 amRNSGroup Financial Director Update
19th Mar 20183:13 pmRNSDirector/PDMR Shareholding
1st Mar 20182:22 pmRNSTotal Voting Rights
19th Feb 20184:30 pmRNSDirector/PDMR Shareholding
12th Feb 201810:32 amRNSDirectorate Change
12th Feb 201810:30 amRNSDirectorate Change
9th Feb 201811:50 amRNSResult of AGM
9th Feb 201811:24 amRNSDirector/PDMR Shareholding
9th Feb 20187:00 amRNSAGM & Q1 IMS
7th Feb 20184:16 pmRNSHolding(s) in Company
6th Feb 20181:44 pmRNSDirectorate Change
1st Feb 201812:13 pmRNSTotal Voting Rights
25th Jan 20189:49 amRNSHolding(s) in Company
17th Jan 20184:25 pmRNSDirector/PDMR Shareholding
4th Jan 201812:06 pmRNSNomination for election of Non-executive Directors
4th Jan 201812:00 pmRNSAnnual Financial Report
29th Dec 201710:00 amRNSTotal Voting Rights
19th Dec 20174:24 pmRNSDirector/PDMR Shareholding
18th Dec 201710:08 amRNSDirector/PDMR Shareholding
8th Dec 20171:19 pmRNSDirector/PDMR Shareholding
5th Dec 201711:39 amRNSDirector/PDMR Shareholding
5th Dec 20177:01 amRNSDirectorate Change
5th Dec 20177:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.